Conference Coverage

Adalimumab strikes out for aortic inflammation in psoriasis

Publish date: June 27, 2018

 

REPORTING FROM IID 2018

The work was funded by the National Institutes of Health and AbbVie, adalimumab’s maker. Among many industry ties, Dr. Gelfand is a consultant for Janssen, maker of ustekinumab, and receives research grants from Janssen and AbbVie.

SOURCE: Gelfand JM et al. IID 2018, Abstract 393.

Pages

Recommended Reading

EADV: Family history of cardiovascular disease is key in psoriasis patients
MDedge Cardiology
Psoriasis tied to abdominal aortic aneurysm in nationwide study
MDedge Cardiology
Effective psoriasis therapy may reduce coronary plaque burden
MDedge Cardiology
Psoriatic arthritis patients have elevated risk for coronary artery plaque
MDedge Cardiology
Psoriasis cardiovascular risk parallels type 2 diabetes
MDedge Cardiology
CV risk factors go undiagnosed, untreated in many psoriatic patients
MDedge Cardiology
Tune in to cardiovascular risk in psoriasis
MDedge Cardiology
Ustekinumab quells aortic inflammation in patients with severe psoriasis
MDedge Cardiology
Psoriasis duration reflects cardiovascular event risk
MDedge Cardiology
CBC values linked to CVD risk in psoriasis
MDedge Cardiology